JPRN-jRCT2033220088招募中1 期
Phase I clinical study on the safety of HER2-specific chimeric antigen receptor (CAR) gene-modified T cell therapy - BP2301-01
Yozo Nakazawa0 个研究点目标入组 12 人开始时间: 2022年5月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 5age old 至 < 65age old（—）
- 性别
- All
入选标准
- •SC1 (before apheresis)
- •1. Patients diagnosed with bone and soft tissue sarcoma or gynecologic malignancies who are refractory or intolerant to standard treatment or have relapsed or progressed after standard treatment
- •2. Patients aged 5 or more to less than 65 at the time of consent
- •3. Patients whose histopathological evaluation confirmed the expression of HER2
- •4. Patients with Karnofsky or Lansky scale of 50 percentage or more
- •5. Patients with target lesions
- •6. Patients with being able to safely perform apheresis
- •7. Patients who meet all of the following for the latest test values
- •-White blood cell count with 1500 per microliter or more
- •-Lymphocyte count with 500 per microliter or more
- •-Hemoglobin with 8.0 grams per deciliter or higher
- •-Platelet count with 75000 per microliter or more
- •-Total bilirubin with 1.5 times or less of the upper limit of reference value
- •-AST with 3 times or less of the upper limit of reference value
- •-ALT with 3 times or less of the upper limit of reference value
- •-Serum creatinine with 2.0 milligrams per deciliter or less
- •-SpO2 with 95 percentage or more (at rest, without oxygen inhalation)
- •8. Patients decided to be normal by echocardiography (left ventricular ejection fraction with 50 percentage or more or left ventricular diameter shortening rate with 30 percentage or more, and no abnormal electrocardiogram with pericardial effusion or requiring treatment)
- •9. Patients who are expected to survive for 3 months or more after obtaining consent
- •10. For participation in the study, written consent has been obtained from the subject or whose surrogate
- •11. Patients willing to participate in the long-term follow-up study
- •SC2 (before treatment)
- •Individuals who meet all SC1 eligibility criteria and meet the following criteria are eligible for inclusion:
- •1. Patients who can supply the investigational product
- •2. Individuals who are unwilling to withdraw consent after SC1 and are aware of the treatment
- •3. Patients treated with salvage chemotherapy who have a 4-week washout period between salvage chemotherapy and initiation of initial lymphodepletion chemotherapy
排除标准
- •SC1 (pre-apheresis), SC2 (pre-treatment initiation)
- •1. Patients with active double cancers
- •2. Patients with concomitant active or serious infections
- •3. Patients with central nervous system metastases
- •4. Patients with a history of coronary artery disease or cerebrovascular disease, or patients with residual sequelae such as paralysis
- •5. Patients with uncontrolled hypertension (resting systolic >160mmHg or diastolic >100mmHg).
- •6. Patients with concomitant pulmonary fibrosis or interstitial pneumonia or a history of uncontrolled concomitant pulmonary disease and imaging findings suspicious for it.
- •7. Patients with uncontrolled diarrhea and diabetes mellitus
- •8. Patients with uncontrolled congestive heart failure, significant heart disease such as arrhythmia, or cerebrovascular disease.
- •New York Heart Association functional classification of heart failure in class III or IV-patients
- •9. Patients with serious complications (renal failure, hepatic failure, active peptic ulcer disease, intestinal paralysis, etc.)
- •10. Patients with concomitant psychosis or psychiatric symptoms who are judged to be difficult to participate in the study.
- •11. Patients with active autoimmune disease
- •12. HIV-positive patients, HTLV-1 positive patients
- •13. Patients who are HBsAg positive or HBc antibody positive and HBV-DNA positive, HCV positive patients
- •14. Subjects who participated in another clinical trial within 6 weeks prior to obtaining informed consent (SC1).
- •15. Individuals who received live vaccination in the 30 days prior to informed consent (SC1).
- •16. Pregnant or breastfeeding patients
- •17. Patients who do not give consent to adequate contraception
- •18. Patients with a history of drug or alcohol dependence or abuse
- •19. Individuals with a history of hypersensitivity reactions to ingredients or additives used in the investigational product (DMSO, albumins)
- •20. Patients with a history of hypersensitivity reactions to pretreatment and premedication
- •21. Other patients who are deemed inappropriate by the investigator or sub-investigator
研究者
相似试验
尚未招募
不适用
Efficacy analysis of anti-HER2 treatment in HER2-enriched early breast cancer identified by PAM50KCT0006154Yonsei University Health System, Gangnam Severance Hospital59
招募中
不适用
A Phase II trial of preoperative HER2 targeting and endocrine therapy in postmenopausal women with HER2 and HR positive breast cancerNeoplasmsKCT0001583Yonsei University Health System, Gangnam Severance Hospital132
已完成
不适用
Research for clinical validation of HER2 protein overexpression and gene amplification assay for salivary gland carcinomaJPRN-UMIN000015960Hokkaido University Hospital26
招募中
1 期
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast CancerAdvanced/ Metastatic Her-2 Positive Breast CancerNCT05575804Fudan University32
尚未招募
1 期
Her1 vaccine in metastatic colon and prostate cancerColorectal Neoplasmsprostate and colon cancerProstatic Neoplasms, Castration-ResistantGenital Neoplasms, MaleUrogenital NeoplasmsProstatic DiseasesGenital Diseases, MaleMale Urogenital DiseasesColonic NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesProstatic NeoplasmsRPCEC00000431Center of Molecular Immunology (CIM)88